Delay in the Initiation of Adjuvant Chemotherapy in Patients with Breast Cancer with Mastectomy with or Without Immediate Breast Reconstruction
Overview
Authors
Affiliations
Background: Patients with breast cancer undergoing mastectomy should be offered the option of immediate breast reconstruction (IBR). The aim of this retrospective study was to assess whether there is a delay in the initiation of adjuvant chemotherapy in patients undergoing mastectomy with or without IBR.
Method: The study included patients aged 70 years or younger with clinically node-negative breast cancer who underwent unilateral mastectomy with IBR (IBR group) or mastectomy alone (no-IBR group) followed by adjuvant chemotherapy at the Helsinki University Hospital between January 2012 to July 2018.
Results: A total of 645 patients were included; 186 in the IBR group and 459 in the no-IBR group. Sixty-six (35.5 per cent) patients in the IBR group and 102 (22.2 per cent) patients in the no-IBR group received their first chemotherapy cycle later than 6 weeks after surgery (P < 0.001). The respective numbers for later than 8 weeks were 17 (9.1 per cent) and 14 (3.1 per cent) (P = 0.001). Among all 645 patients, postoperative complications were a significant risk factor for a delay in the initiation of chemotherapy. Sixty-seven (39.9 per cent) patients with and 101 (21.2 per cent) patients without complications had a delay in chemotherapy (P < 0.001). The delay in chemotherapy was due to complications in 39 (59.1 per cent) in the IBR group and in 28 (27.5 per cent) in the no-IBR group (P < 0.001).
Conclusion: Patients undergoing mastectomy alone were more likely to receive adjuvant chemotherapy within 6 weeks after surgery compared with the IBR patients. IBR significantly increased the risk of postoperative complications in comparison with mastectomy alone. The complications, in turn, were a significant risk factor for delay in adjuvant chemotherapy.
Maritano E, Kaciulyte J, Sordi S, Marcasciano M, Lo Torto F, Luridiana G Aesthetic Plast Surg. 2024; .
PMID: 39511019 DOI: 10.1007/s00266-024-04501-4.
Zhu E, Zhang L, Wang J, Hu C, Jing Q, Shi W Cancer Innov. 2024; 3(3):e119.
PMID: 38947759 PMC: 11212336. DOI: 10.1002/cai2.119.
Walsh R, Lofters A, Groome P, Moineddin R, Krzyzanowska M, Griffiths R Cancer Causes Control. 2024; 35(9):1245-1257.
PMID: 38748276 DOI: 10.1007/s10552-024-01879-z.
Oncoplastic Breast Reconstruction in Morbidly Obese Patients: An Acceptable Practice.
Fortenbery G, Todd L, Nazir N, Dalla S, Collins M Plast Reconstr Surg Glob Open. 2024; 12(2):e5601.
PMID: 38348460 PMC: 10861004. DOI: 10.1097/GOX.0000000000005601.